Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 20,671 shares, a decrease of 16.4% from the January 15th total of 24,740 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 203,426 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 203,426 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, BTIG Research reduced their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $1.50.

Xtant Medical Stock Up 0.2%

NYSEAMERICAN:XTNT traded up $0.00 during mid-day trading on Monday, reaching $0.58. The company’s stock had a trading volume of 38,169 shares, compared to its average volume of 183,153. The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35. Xtant Medical has a 1 year low of $0.34 and a 1 year high of $0.95. The stock has a fifty day moving average of $0.69 and a 200-day moving average of $0.68. The firm has a market capitalization of $81.83 million, a PE ratio of 58.51 and a beta of -0.04.

Institutional Trading of Xtant Medical

Several hedge funds and other institutional investors have recently made changes to their positions in XTNT. AWM Investment Company Inc. acquired a new position in shares of Xtant Medical in the 2nd quarter valued at $4,875,000. Crescent Grove Advisors LLC increased its stake in shares of Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 200,000 shares in the last quarter. Wiregrass Investment Management LLC acquired a new stake in Xtant Medical in the 4th quarter valued at $81,000. Renaissance Technologies LLC increased its holdings in Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares in the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.